{
 "meta": {
  "api_version": "1.0.0",
  "dataset_version": "2.0.1+unreleased",
  "live_matches_release": false,
  "archived_release": {
   "version": "2.0.1",
   "version_doi": "10.5281/zenodo.23090261",
   "date": "2026-10-01",
   "studies": 428
  },
  "data_fingerprint": "21bd609b55973b7b5b84e545fdde629d79115243854f1595680c534e6e1ef96f",
  "corpus_snapshot": "2026-11-02T19:05:06+0100",
  "source_commit": "1e9de0d56d4ea503818c4095460addc4a0c7f4a3",
  "license": "CC-BY-4.0",
  "cite": "Barton O. Oliver's mTOR Atlas (live data, not an archived version; give corpus_snapshot and source_commit). doi:10.5281/zenodo.22059963",
  "docs": "https://mtor-atlas.org/api/"
 },
 "data": {
  "id": "EVE-TSC",
  "claim": "Everolimus inhibits Tuberous sclerosis complex",
  "source": {
   "name": "Everolimus",
   "entity": "everolimus"
  },
  "target": {
   "name": "Tuberous sclerosis complex",
   "entity": "tuberous-sclerosis-complex"
  },
  "effect": "inhibits",
  "type": "clinical-outcome",
  "directness": "indirect",
  "timescale": "chronic",
  "compartment": null,
  "map_band": "outcome",
  "species": [
   "human"
  ],
  "mechanism": "EXIST trials: everolimus shrank the brain tumours (SEGA) and kidney lesions of tuberous sclerosis - treating the pathway the mutation switches on, rather than a downstream symptom. The gene defect itself remains.",
  "mechanism_beginner": "In patients with the genetic disease tuberous sclerosis, everolimus shrank both brain and kidney tumours. It works one step downstream of the mutation: it replaces the brake the mutation removed, so the tumours shrink while the drug is given and regrow when it stops. The mutation itself is untouched.",
  "context": null,
  "boundary": "Lesions regrow when the drug is stopped - this is suppression, not cure.",
  "boundary_tags": [
   "reversible-on-withdrawal"
  ],
  "conflict": null,
  "note": "The purest case in the Atlas: known gene, known pathway, matched drug, randomised evidence.",
  "consensus_contested": false,
  "curation_contested": false,
  "contested": false,
  "confidence": {
   "mechanistic": "high",
   "human_relevance": "established",
   "consensus": "established"
  },
  "evidence": {
   "kind": "Pharmacological",
   "strongest": {
    "code": "H",
    "label": "Human study"
   },
   "supporting": [
    "KRU2010",
    "BIS2013",
    "GAO2026B"
   ],
   "conflicting": []
  },
  "external_refs": [],
  "reviewed": null,
  "updated": null,
  "checked": null,
  "review_status": "unreviewed",
  "reviewer": null,
  "curation_status": "Proposed",
  "url": "https://mtor-atlas.org/relation/EVE-TSC/",
  "api_url": "https://mtor-atlas.org/api/v1/relations/EVE-TSC.json"
 }
}